

OMB NUMBER 3235-0104
EXPIRES: SEPTEMBER 30, 1998
ESTIMATED AVERAGE BURDEN
HOURS PER RESPONSE .....0.5

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f)
of the Investment Company Act of 1940

<TABLE>

Table with 6 columns: 1. Name and Address of Reporting Person, 2. Date of Event Requiring Statement, 3. Trading Symbol, 4. Issuer Name and Ticker or of Original, 6. If Amendment, Date. Includes entry for LIGAND PHARMACEUTICALS INCORPORATED and SERAGEN, INC. (SRGN).

TABLE 1 -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED

Table with 4 columns: 1. Title of Security, 2. Amount of Securities Beneficially Owned, 3. Ownership Form: Direct (D) or Indirect (I), 4. Nature of Indirect Beneficial.

NO SECURITIES OWNED(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
\*If the form is filed by more than one Reporting Person, see Instruction 4(b)(v).

(Print or Type Responses) (Over) SEC 2270 (7-96)

</TABLE>
FORM 3 (CONTINUED)

TABLE II -- DERIVATIVE SECURITIES BENEFICIALLY OWNED
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)

<TABLE>

<S>	<C>	<C>	<C>	<C>	<C>
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security:	5. Ownership Form of (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title	Amount or Number of Shares	Direct (D) or Indirect (I) (Instr. 5)	

</TABLE>

Explanation of Responses:

(1) Ligand has acquired voting power with respect to certain matters of shares of common stock and preferred stock of Seragen, Inc. representing, on an as-converted basis, 118,654,461 shares of common stock of Seragen, Inc. through irrevocable proxies granted to Ligand by certain directors, officers and stockholders of Seragen, Inc. Ligand does not have any pecuniary interest in the shares.

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, See Instruction 6 for procedure.

Ligand Pharmaceuticals Incorporated

By: \_\_\_\_\_ Date: May 21, 1998

/s/ WILLIAM L. RESPASS  
 William L. Respass, Vice President,  
 General Counsel, Government Affairs